| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
|
| ln Vitro |
Erdosteine is an oral mucolytic drug that is utilized in many chronic respiratory disorders as an expectorant. By preventing NF-κB activation in LPS-stimulated murine macrophages, eugenosteine reduces inflammation. Erdosteine, however, does not prevent the phosphorylation of the Akt and MAPK pathways brought on by LPS. Cell viability was assessed in order to assess the harmful effects of erdosteine on macrophages. Erdosteine at 1, 10, or 100 μg/mL did not cause any observable cytotoxicity. In RAW 264, LPS (1 μg/mL) treatment caused IκBα degradation.7 cells, RAW 264, with the highest deterioration seen after 10 minutes.Erdosteine at the specified concentrations was pretreated for 6 hours on 7 cells, and after that, LPS (1 μg/mL) was added after 10 minutes. The baseline levels of IκBα were unaffected by the ergotoxine pretreatment. Baseline levels of IκBα were unaffected by treatment with DMSO alone in a volume equivalent to that used for erdosteine administration. After 10 minutes of LPS treatment, there was a drop in the quantity of IκBα. IκBα degradation can be successfully inhibited by pretreatment with erdosteine at the prescribed concentration and time [1].
|
|---|---|
| ln Vivo |
The following four groups of 26 male mice were created: Groups 1–4: control; Group 2–4: methotrexate (MTX) treatment; Group 5–6: MTX + Erdosteine treatment. On the first day of the trial, Groups 2 and 4 received a single oral dose of erdosteine every day for seven days, whereas Groups 3 and 4 received a single intraperitoneal injection of methotrexate. Upon completion of the study, the animals' testicles were extracted and weighed. Comparing the methotrexate group to the control group, there was a significant difference (p<0.05) in the total antioxidant capacity, total oxidative stress level, and myeloperoxidase activity. Between the methotrexate group and the control group, there was no difference in the levels of lipid peroxidation. In conclusion, methotrexate-induced toxicity to the testicles is effectively prevented by erdosteine. By causing spermatogenesis to develop in the seminiferous tubules, co-administration of erdosteine and methotrexate heals testicular injury [2].
|
| References |
[1]. Park JS, et al. Anti-inflammatory Effect of Erdosteine in Lipopolysaccharide-Stimulated RAW 264.7 Cells. Inflammation. 2016 Aug;39(4):1573-81.
[2]. Oktar S, et al. Beneficial effect of erdosteine on methotrexate-induced testicular toxicity in mice. Toxicol Ind Health. 2010 Aug;26(7):433-8. [3]. Recipharm’s proprietary molecule Erdosteine recognised as COPD treatment |
| Molecular Formula |
C8H11NO4S2
|
|---|---|
| Molecular Weight |
249.29
|
| Exact Mass |
249.0129
|
| CAS # |
84611-23-4
|
| Related CAS # |
Erdosteine-13C4;Erdosteine-d4
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
S1C(C([H])(C([H])([H])C1([H])[H])N([H])C(C([H])([H])SC([H])([H])C(=O)O[H])=O)=O
|
| Synonyms |
Erdosteine PV144 PV 144 RV 144 RV144 PV-144
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~200.55 mM)
H2O : ~6.67 mg/mL (~26.75 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3.25 mg/mL (13.04 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 32.5 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 3.25 mg/mL (13.04 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 32.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3.25 mg/mL (13.04 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 6.67 mg/mL (26.75 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0114 mL | 20.0570 mL | 40.1139 mL | |
| 5 mM | 0.8023 mL | 4.0114 mL | 8.0228 mL | |
| 10 mM | 0.4011 mL | 2.0057 mL | 4.0114 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
